What is it about?
Inclusion body myositis (IBM) is a muscle disease affecting adults over 50, causing progressive weakness and disability due to inflammation and muscle degeneration. No effective treatments exist, and the complex mix of these processes makes it hard to understand the disease or find new therapies. Our study used advanced protein analysis to compare muscle samples from 28 IBM patients and 28 healthy individuals, identifying 627 proteins that differed significantly. These proteins showed signs of inflammation, disrupted energy use in cells, and problems with muscle repair. We pinpointed KDM5A, a protein that regulates gene activity and muscle cell development, as a key player driving IBM’s disease processes. Another protein, RB1, was found to be suppressed, and KDM5A interacts with it, linking core IBM features. To confirm our findings, we examined muscle tissue and saw more muscle cell nuclei with myogenin (a marker of muscle repair) in IBM patients, with higher KDM5A levels in these cells compared to healthy controls. Lab experiments showed KDM5A is present in early muscle cells but decreases as they mature, supporting its role in faulty muscle repair. Using a drug to block KDM5A reduced harmful protein buildup in a lab model mimicking IBM. This study confirms known IBM issues while revealing new details about its protein landscape, especially faulty energy use and muscle repair. KDM5A’s role as a potential driver offers a promising target for future research and treatments.
Featured Image
Photo by Maria Kovalets on Unsplash
Why is it important?
This study is important because it helps us better understand inclusion body myositis (IBM), a muscle disease that weakens people over 50 and has no effective treatments. By analyzing proteins in muscle tissue, the study reveals how inflammation, faulty muscle repair, and energy problems in cells contribute to IBM. It identifies KDM5A, a protein that may drive these issues, offering a new clue about what goes wrong in the disease. This is exciting because it points to a potential target for future treatments. The study also confirms known problems in IBM while uncovering new details, like disrupted energy pathways, which could lead to better ways to diagnose or treat the disease. Ultimately, it brings hope for developing therapies to improve the lives of people with IBM.
Perspectives
As a researcher dedicated to unraveling the complexities of age-related diseases, I find this study on inclusion body myositis (IBM) profoundly compelling. IBM’s devastating impact on muscle strength in older adults, coupled with the absence of effective therapies, underscores the urgency of this work. Our use of high-resolution proteomics to map 627 differentially expressed proteins in IBM muscle tissue is a significant leap forward. It not only confirms the interplay of inflammation and impaired muscle repair but also sheds light on disrupted cellular energy pathways—key insights that deepen our understanding of IBM’s pathology. The identification of KDM5A as a potential upstream regulator is particularly exciting. Its role in gene regulation and muscle cell development, validated through experiments showing its presence in immature muscle cells and its influence on harmful protein buildup, positions KDM5A as a promising therapeutic target. This discovery aligns with my belief that targeting molecular hubs can untangle complex disease processes. The study’s rigorous approach, blending unbiased proteomics with targeted validation, sets a robust foundation for future research. From my perspective, this work is a beacon of hope for IBM patients. By illuminating novel aspects of the disease and pinpointing actionable targets like KDM5A, it paves the way for innovative treatments. I eagerly anticipate seeing how these findings inspire further exploration and, ultimately, solutions to alleviate the burden of IBM.
Professor Stuart Maudsley
H. Lee Moffitt Cancer Center
Read the Original
This page is a summary of: Ageing Signatures and Disturbed Muscle Regeneration in Muscle Proteome of Inclusion Body Myositis, Journal of Cachexia Sarcopenia and Muscle, June 2025, Wiley,
DOI: 10.1002/jcsm.13845.
You can read the full text:
Contributors
The following have contributed to this page
